News | Prostate Cancer | December 18, 2015

Cancer Targeted Technology Receives $2.3 Million Small Business Fast-Track Contract to Develop an Innovative PSMA-Targeted Radionuclide Therapy for Prostate Cancer

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology firm focusing on cancer diagnostics and therapeutics, announced that the National Cancer Institute awarded a 27-month, $2.3M contract to CTT to develop a new agent that will help treat metastatic prostate cancer. Prostate cancer is the most commonly diagnosed cancer and second leading cause of cancer death in men. The cancer is radiosensitive but no radiotherapy to date specifically targets this cancer. CTT is developing molecules that bind Prostate-Specific Membrane Antigen (PSMA) for the specific delivery of diagnostic and therapeutic agents. PSMA is an excellent biomarker as its expression is minimal to negative on normal tissues, but is over-expressed on prostate cancer and expression increases as the cancer metastasizes and becomes castrate-resistant. CTT’s unique phosphoramidate-based agents, discovered by Cliff Berkman, M.d., professor of chemistry, Washington State University, bind irreversibly to PSMA. Unlike other agents targeting PSMA, this distinctive mode of binding enhances uptake and internalization by tumor cells, leading to increased accumulation of the therapeutic payload within the tumor and improved efficacy, with minimal side effects to healthy tissues.

CTT is excited to work with Carolyn Anderson, M.D., professor of radiology and head of the Molecular Imaging Laboratory at the University of Pittsburgh, on this contract. Anderson’s group, working in state-of-the-art facilities, will radiolabel and evaluate CTT’s agents in preclinical prostate tumor models and will monitor the efficacy in conjunction with CTT’s diagnostic imaging agent.

This contract optimizes the lead agent, CTT1401, to specifically deliver a therapeutic dose of the radionuclide, 177Lu, to prostate tumors and will advance this compound to an Investigational New Drug application that would support a clinical trial in metastatic prostate cancer. The radiotherapeutic agent will be used in conjunction with CTT’s companion diagnostic Positron Emission Tomography imaging agent, CTT1057 (set to commence clinical trials in prostate cancer patients in early 2016).

“Although new treatments have emerged for metastatic prostate cancer, overall survival rates remain poor. A specific means of treating this disease that minimizes side effects and results in a meaningful increase in quality of life and life expectancy is needed, and we believe CTT’s new radiotherapy agent will accomplish this goal,” stated Beatrice Langton-Webster, M.d., CTT’s chief executive officer and principal investigator on the contract.

For more information: www.cancertargetedtechnology.com

Related Content

Study Unveils Blueprint for Treating Radiation-Resistant Brain Tumor

NIH-funded researchers showed how gliomas may be treated with radiation and drugs that block DNA repair. Image courtesy of Castro lab, Michigan Medicine, Ann Arbor

 

News | Radiation Therapy | February 19, 2019
February 19, 2019 — Researchers at the University of Michigan recently searched for new brain tumor treatments by exp
Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial
News | Radiopharmaceuticals and Tracers | January 30, 2019
ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof